SARS-CoV-2 Drives JAK1/2-Dependent Local Complement Hyperactivation

Scientists unexpectedly found that the complement system was one of the intracellular pathways most highly induced by SARS-CoV-2 infection in lung epithelial cells.
[Science Immunology]
Yan, B., Freiwald, T., Chauss, D., Wang, L., West, E., Mirabelli, C., Zhang, C. J., Nichols, E.-M., Malik, N., Gregory, R., Bantscheff, M., Ghidelli-Disse, S., Kolev, M., Frum, T., Spence, J. R., Sexton, J. Z., Alysandratos, K. D., Kotton, D. N., Pittaluga, S., … Kazemian, M. (2021). SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation. Science Immunology, 6(58). https://doi.org/10.1126/sciimmunol.abg0833 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Durability of Immunity to SARS-CoV-2 and Other Respiratory Viruses

The authors summarize what is now known about adaptive immunity to SARS-CoV-2 and draw comparisons with immunity to other respiratory viruses, focusing on the longevity of protective responses.
[Trends in Microbiology]
Siggins, M. K., Thwaites, R. S., & Openshaw, P. J. M. (2021). Durability of immunity to SARS-CoV-2 and other respiratory viruses. Trends in Microbiology, 0(0). https://doi.org/10.1016/j.tim.2021.03.016 Cite
AbstractFull Article
Bookmark

No account yet? Register

0
Share

A Single Dose of Self-Transcribing and Replicating RNA Based SARS-CoV-2 Vaccine Produces Protective Adaptive Immunity In Mice

Activation of cell mediated immunity produced a strong viral antigen specific CD8+ T lymphocyte response.
[Molecular Therapy]
Alwis, R. de, Gan, E. S., Chen, S., Leong, Y. S., Tan, H. C., Zhang, S. L., Yau, C., Low, J. G. H., Kalimuddin, S., Matsuda, D., Allen, E. C., Hartman, P., Park, J., Alayyoubi, M., Bhaskaran, H., Dukanovic, A., Bao, Y., Clemente, B., Vega, J., … Ooi, E. E. (2021). A Single Dose of Self-Transcribing and Replicating RNA Based SARS-CoV-2 Vaccine Produces Protective Adaptive Immunity In Mice. Molecular Therapy, 0(0). https://doi.org/10.1016/j.ymthe.2021.04.001 Cite
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

SARS-CoV-2 Mutations Acquired in Mink Reduce Antibody-Mediated Neutralization

Scientists report that mutations frequently found in the S proteins of SARS-CoV-2 from mink were mostly compatible with efficient entry into human cells and its inhibition by soluble ACE2.
[Cell Reports]
Hoffmann, M., Zhang, L., Krüger, N., Graichen, L., Kleine-Weber, H., Hofmann-Winkler, H., Kempf, A., Nessler, S., Riggert, J., Winkler, M. S., Schulz, S., Jäck, H.-M., & Pöhlmann, S. (2021). SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization. Cell Reports, 0(0). https://doi.org/10.1016/j.celrep.2021.109017 Cite
AbstractFull ArticleGraphical Abstract
Bookmark

No account yet? Register

0
Share

The Neutralizing Antibody, LY-CoV555, Protects against SARS-CoV-2 Infection in Non-human Primates

Researchers report that high-throughput microfluidic screening of antigen-specific B-cells led to the identification of LY-CoV555, a potent anti-spike neutralizing antibody from a hospitalized, convalescent patient with COVID-19.
[Science Translational Medicine]
Jones, B. E., Brown-Augsburger, P. L., Corbett, K. S., Westendorf, K., Davies, J., Cujec, T. P., Wiethoff, C. M., Blackbourne, J. L., Heinz, B. A., Foster, D., Higgs, R. E., Balasubramaniam, D., Wang, L., Zhang, Y., Yang, E. S., Bidshahri, R., Kraft, L., Hwang, Y., Žentelis, S., … Falconer, E. (2021). The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in non-human primates. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.abf1906 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Designed Proteins Assemble Antibodies into Modular Nanocages

Researchers developed an approach to designing proteins that position antibodies or Fc-fusions on the twofold symmetry axes of regular dihedral and polyhedral architectures.
[Science]
Divine, R., Dang, H. V., Ueda, G., Fallas, J. A., Vulovic, I., Sheffler, W., Saini, S., Zhao, Y. T., Raj, I. X., Morawski, P. A., Jennewein, M. F., Homad, L. J., Wan, Y.-H., Tooley, M. R., Seeger, F., Etemadi, A., Fahning, M. L., Lazarovits, J., Roederer, A., … Baker, D. (2021). Designed proteins assemble antibodies into modular nanocages. Science, 372(6537). https://doi.org/10.1126/science.abd9994 Cite
Abstract
Bookmark

No account yet? Register

0
Share

T Cell Assays Differentiate Clinical and Subclinical SARS-CoV-2 Infections from Cross-Reactive Antiviral Responses

Scientists showed a range of T cell assays that differentially captured immune function to characterise SARS-CoV-2 responses.
[Nature Communications]
Ogbe, A., Kronsteiner, B., Skelly, D. T., Pace, M., Brown, A., Adland, E., Adair, K., Akhter, H. D., Ali, M., Ali, S.-E., Angyal, A., Ansari, M. A., Arancibia-Cárcamo, C. V., Brown, H., Chinnakannan, S., Conlon, C., de Lara, C., de Silva, T., Dold, C., … Dunachie, S. (2021). T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. Nature Communications, 12(1), 2055. https://doi.org/10.1038/s41467-021-21856-3 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Influenza Virus and SARS-CoV-2: Pathogenesis and Host Responses in the Respiratory Tract

The authors discuss what is known about SARS-CoV-2 in the context of the broad knowledge of influenza virus, highlighting the similarities and differences between the respiratory viruses.
[Nature Reviews Microbiology]
Flerlage, T., Boyd, D. F., Meliopoulos, V., Thomas, P. G., & Schultz-Cherry, S. (2021). Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract. Nature Reviews Microbiology, 1–17. https://doi.org/10.1038/s41579-021-00542-7 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Endothelial Dysfunction and Immunothrombosis as Key Pathogenic Mechanisms in COVID-19

Scientists propose that SARS-CoV-2 infection induces a process known as immunothrombosis, in which activated neutrophils and monocytes interact with platelets and the coagulation cascade, leading to intravascular clot formation in small and larger vessels.
[Nature Reviews Immunology]
Bonaventura, A., Vecchié, A., Dagna, L., Martinod, K., Dixon, D. L., Van Tassell, B. W., Dentali, F., Montecucco, F., Massberg, S., Levi, M., & Abbate, A. (2021). Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nature Reviews Immunology, 1–11. https://doi.org/10.1038/s41577-021-00536-9 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Hypoxic and Pharmacological Activation of HIFs Inhibits SARS-CoV-2 Infection of Lung Epithelial Cells

Scientists demonstrated that hypoxia and the hypoxia inducible factor (HIF) prolyl hydroxylase inhibitor Roxadustat reduced angiotensin-converting enzyme expression and inhibited SARS-CoV-2 entry and replication in lung epithelial cells via a HIF-1α dependent pathway.
[Cell Reports]
Wing, P. A., Keeley, T. P., Zhuang, X., Lee, J. Y., Prange-Barczynska, M., Tsukuda, S., Morgan, S. B., Harding, A. C., Argles, I. L. A., Kurlekar, S., Noerenberg, M., Thompson, C. P., Huang, K.-Y. A., Balfe, P., Watashi, K., Castello, A., Hinks, T. S., James, W., Ratcliffe, P. J., … McKeating, J. A. (2021). Hypoxic and pharmacological activation of HIFs inhibits SARS-CoV-2 infection of lung epithelial cells. Cell Reports, 0(0). https://doi.org/10.1016/j.celrep.2021.109020 Cite
AbstractFull ArticleGraphical Abstract
Bookmark

No account yet? Register

0
Share

Vir Biotechnology Announces New Preclinical Research Demonstrating VIR-7831 Maintains Neutralizing Activity Against the SARS-CoV-2 California Variant

Vir Biotechnology, Inc. announced new preclinical research demonstrating the ability of VIR-7831, the company’s investigational SARS-CoV-2 monoclonal antibody, to maintain its neutralizing activity against a mutation in the receptor binding domain of SARS-CoV-2, called L452R, which is found in the California variant.
[Vir Biotechnology, Inc. (Globe Newswire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share
Share